Top Nootropic Peptide Codes in 2026: Semax, Selank, Adamax, Adalank, Dihexa and More, Decoded

For research and educational purposes only. Not medical advice.

This guide explains nootropic peptide names, variants and identification: Semax versus N-Acetyl Semax Amidate, the different labels used for Adamax, and the distinction between Adamax and the Selank-related name Adalank. Its purpose is to help readers understand what a name claims about a compound, not to rank compounds or recommend their use.

Vendor names and shorthand are not interchangeable with a documented chemical identity. Compare the stated sequence or structure, terminal modifications, theoretical mass and laboratory identification method. A matching mass alone may not distinguish every structural variant, and findings on a parent compound should not automatically be attributed to a modified version.

For an evidence-focused comparison instead, see our Top 5 nootropic peptides research review. This article stays focused on naming, variants and identification.

Why Peptide Naming Conventions Matter More Than Most People Realize

Before getting into the individual compounds, the naming problem deserves direct treatment because it has real consequences for sourcing and COA verification.

Research peptides are named inconsistently across the market for several reasons. Some names are generic compound identifiers. Some are brand names created by vendors or the original research labs. Some names refer to modification states of the same underlying sequence. And some names have been repurposed by different vendors to mean different things entirely.

The only way to know definitively what a compound is at the molecular level is the mass spectrometry peak on a COA from an independent third-party laboratory. The molecular weight measured by LC-MS is unambiguous. It does not care what the vendor called the compound on the label. A dominant peak at 855 Da is N-Acetyl Semax Amidate. A dominant peak at 984 Da is Adamax. A dominant peak at 780 Da is standard unmodified Semax. These numbers do not lie and vendor labels sometimes do.

With that established, here is the complete breakdown of every major nootropic peptide in the 2026 research community.

The Semax Family: One Backbone, Four Distinct Compounds

The Semax family is the most structurally complex product line in the nootropic peptide market because the parent compound has been modified in multiple ways that produce meaningfully different pharmacokinetic behavior. Understanding the family requires understanding the underlying ACTH-derived backbone and what each modification does to it.

Standard Semax

Standard Semax is a synthetic heptapeptide derived from the ACTH 4-10 fragment with a Pro-Gly-Pro extension added for stability. It was developed at the Institute of Molecular Genetics in Russia and has over 100 peer-reviewed publications behind it. Its primary mechanism involves melanocortin receptor activation (MC4R), BDNF upregulation of approximately 1.4 times protein and 3 times mRNA, NGF upregulation, dopaminergic and serotonergic modulation, and cholinergic enhancement.

The limitation of standard Semax is its half-life. Both ends of the peptide chain are exposed to enzymatic attack. Aminopeptidases attack from the N-terminus. Carboxypeptidases attack from the C-terminus. The compound degrades in 30 to 60 minutes, requiring multiple daily doses for consistent research protocols. Every modification in the family addresses this problem.

This is the form used in all Russian clinical trials. When readers read published research on Semax, they are reading data on this unmodified version.

N-Acetyl Semax Amidate (NASA)

N-Acetyl Semax Amidate, abbreviated NASA in the research community, is the dual-terminally-modified version of standard Semax. The 75 Da mass increase over standard Semax reflects the acetyl group at the N-terminus and the amide group at the C-terminus.

The acetyl cap at the N-terminus physically blocks aminopeptidase access. The amide cap at the C-terminus physically blocks carboxypeptidase access. Both enzymatic entry points are eliminated. The core MEHFPGP sequence is unchanged and retains full biological activity. Half-life extends to 4 to 8 hours.

This is the practical default entry point for researchers new to the Semax family. It has the most vendor availability, the clearest COA verification pathway, and well-documented pharmacokinetic behavior relative to standard Semax. It is not a compromise version. It is a genuinely superior compound to standard Semax in every pharmacokinetic respect while preserving identical mechanistic activity.

Adamax

Adamax is a nine-amino-acid research peptide built on the Semax backbone with two structural additions beyond N-Acetyl Semax Amidate. The N-terminal acetyl cap is retained. The C-terminus receives an adamantylglycine extension rather than a simple amide cap. The adamantane group is a rigid polycyclic hydrocarbon cage structure that is chemically inert and physically bulky.

The adamantane modification does two things that matter practically. It creates steric hindrance at the C-terminus that physically prevents carboxypeptidase access more aggressively than amidation alone. It also increases the compound's lipophilicity, making it more fat-soluble and therefore more capable of crossing the blood-brain barrier through passive membrane diffusion in addition to the olfactory nerve pathway used by all intranasal compounds in this family.

The 984 Da molecular weight is 129 Da heavier than N-Acetyl Semax Amidate. That 129 Da difference is the adamantylglycine modification. When a third-party laboratory runs LC-MS on a vial labeled Adamax and returns a dominant peak at 855 Da rather than 984 Da, the label is wrong. The vial contains N-Acetyl Semax Amidate. This mislabeling pattern has been documented in the 2026 market and is precisely why mass spectrometry identification on the COA is non-negotiable for this compound specifically.

One important clarification: some vendors use "Adamax" as a brand name for a combined Semax-plus-Selank blend. This is a vendor naming choice, not the compound's structural identity. The actual compound Adamax is the N-Acetyl Semax with adamantane modification described here. If readers see "Adamax" on a vendor page and the COA shows two distinct mass peaks consistent with Semax and Selank sequences rather than a single 984 Da peak, they have a blend, not the structural compound.

N-Acetyl Adamax Amidate

N-Acetyl Adamax Amidate stacks all three structural modifications: the N-terminal acetyl cap, the adamantane modification, and a C-terminal amide end-cap applied to the adamantane group itself. Every enzymatic entry point is addressed. The 1032 Da molecular weight is 48 Da heavier than standard Adamax, reflecting the additional amide cap.

Theoretically the most pharmacokinetically optimized compound in the family. Practically, as of mid-2026, only two vendors have confirmed verified 1032 Da product with mass spectrometry documentation: Atomik Labz and Solution Peptides. If readers are sourcing anything labeled N-Acetyl Adamax Amidate from any other vendor, require the COA to specify a dominant mass spec peak at 1032 Da before accepting it. A peak at 984 Da means readers have standard Adamax, correctly or mislabeled depending on the vendor.

The Selank Family: The Anxiolytic Branch

The Selank family parallels the Semax family in its structural evolution from parent compound through modified derivatives, but operates through a mechanistically distinct pathway targeting the anxiety and stress-modulation axis of cognitive function rather than the neurotrophic axis.

Standard Selank

Selank is a synthetic heptapeptide analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) found in immunoglobulin G. The research team at the same Russian institute that developed Semax added the Pro-Gly-Pro extension to the tuftsin sequence to improve CNS activity. The resulting compound has been used as a prescription pharmaceutical in Russia for anxiety disorders.

The primary mechanism involves inhibition of enkephalinase, the enzyme that breaks down enkephalins, the brain's endogenous opioid peptides involved in mood regulation and stress response. This extends enkephalin activity and supports mood stability without receptor tolerance or dependence. Selank also modulates GABA-A receptor activity to produce anxiolytic effects without sedation, upregulates BDNF in hippocampal tissue through limbic circuits, and influences over 2,000 gene expression targets according to microarray research.

A 14-day clinical trial in 62 patients with generalized anxiety disorder found anxiolytic effects comparable to medazepam, with 40 percent of patients experiencing rapid response within 1 to 3 days and no tolerance, dependence, or withdrawal. That human clinical data distinguishes Selank from most other peptides in this category.

N-Acetyl Selank Amidate (Adalank)

Adalank is the terminally modified version of Selank, applying the same structural logic that N-Acetyl Semax Amidate applies to the Semax backbone. N-acetylation at the N-terminus blocks aminopeptidase degradation. C-terminal amidation blocks carboxypeptidase degradation and improves receptor binding affinity. The 880 Da molecular weight reflects these two modifications over the 751 Da parent compound.

The clinical data from standard Selank's anxiolytic trials is the evidence base that Adalank's structural modifications are designed to preserve and enhance through improved bioavailability. Adalank is the natural companion to Adamax in next-generation nootropic research stacks, addressing the stress-modulation axis while Adamax addresses the neurotrophic axis. Together the pair mirrors and extends the Semax-Selank research relationship that has defined the cognitive peptide field.

Dihexa: The Synaptogenic Outlier

Dihexa stands structurally and mechanistically apart from everything else in this guide. It is not derived from ACTH fragments. It is not a tuftsin analog. It operates through a completely different biological system.

Dihexa is a synthetic hexapeptide derived from angiotensin IV, developed at Washington State University. It is an HGF mimetic, meaning it binds hepatocyte growth factor with high affinity and activates c-Met receptors on neurons to drive synaptogenesis, the physical formation of new synaptic connections. This mechanism is structurally distinct from BDNF-mediated neuroplasticity. Where Semax family compounds upregulate neurotrophic signaling, Dihexa drives the physical building of synaptic architecture.

The N-terminal hexanoyl group is the modification that gives Dihexa its stability characteristics and distinguishes it analytically from its parent angiotensin IV sequence. The molecular weight at 812 Da reflects the full modified sequence including this modification.

The 2025 retraction of the foundational 2014 HGF/c-Met mechanistic paper due to image manipulation concerns is the critical evidentiary caveat that responsible coverage of Dihexa requires. The retraction affects the specific causal mechanism paper, not the original 2013 synthesis paper or the 2021 independent Chinese replication study. The mechanism remains biologically plausible. The evidence base is more contested than it was before April 2025. Researchers approaching Dihexa need the full picture.

The HGF/c-Met signaling pathway also drives cellular proliferation, which is the same pathway involved in certain cancer biology. This shared biology is a theoretical concern that does not have documented clinical evidence at research doses but warrants conservative cycling protocols and medical monitoring.

Noopept: The Bioavailable Outlier

Noopept occupies a different structural category from the other compounds in this guide. It is a synthetic dipeptide analog, not a natural peptide or a peptide derived from an endogenous signaling sequence.

Noopept is approximately 1,000 times more potent by dose than piracetam, active at 10 to 30 mg per day. It is a prodrug. After administration it is metabolized in the brain to cycloprolylglycine, an endogenous neuropeptide that acts as a positive allosteric modulator of AMPA glutamate receptors. This AMPA receptor modulation facilitates long-term potentiation, the cellular mechanism underlying memory formation and consolidation.

The phenylacetyl N-terminus modification and ethyl ester C-terminus modification are what give Noopept its oral bioavailability, the most practically significant distinguishing feature among all compounds in this guide. The modifications allow the compound to survive gastrointestinal transit and be absorbed intact before conversion to its active form in the brain. No needle. No nasal spray required.

Noopept is approved in Russia for cognitive disorders of vascular and traumatic origin based on Phase III clinical trial data. It has the strongest oral bioavailability and the most accessible dosing protocol of any compound covered here.

Cerebrolysin: The Complex Mixture

Cerebrolysin does not have a single defined sequence because it is not a single compound. It is a standardized mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue.

Cerebrolysin's analytical complexity makes it impossible to assign a single sequence or molecular weight. A COA for Cerebrolysin specifies the source, the manufacturing process, and activity assays rather than a single mass spectrometry peak. This is the sourcing and verification challenge that distinguishes it from single-sequence compounds.

What Cerebrolysin has that no other compound in this guide can match is controlled trial data at scale. A 2025 meta-analysis reviewed 8 randomized controlled trials involving 1,842 subjects and found Cerebrolysin reduced disability by 22 percent at 6 months post-traumatic brain injury when initiated within 24 hours. That is controlled trial evidence in humans, not preclinical extrapolation.

The intravenous administration requirement is the practical barrier. Cerebrolysin requires clinical-level setup that intranasal compounds like Semax, Selank, and their derivatives do not.

The Complete Nootropic Peptide Reference Table

This table maps every compound covered in this guide to its sequence, molecular weight, mechanism, primary application, and administration route. Use it to verify COA documentation and to understand what readers are actually sourcing when they see these names on vendor pages.

How to Use This Table for COA Verification

When readers receive a COA for any compound in this table, locate the identification section. It should specify the method used (LC-MS or equivalent) and the observed molecular mass. The described verification process includes matching the observed mass against the values in the table.

A result within approximately 1 to 2 Da of the expected value is a match. A result more than 5 Da away from the expected value requires explanation. A result that matches a different compound in the table means the product is mislabeled.

The single most important verification: if the label says Adamax and the mass spec shows 855 Da, readers have N-Acetyl Semax Amidate. If the label says N-Acetyl Adamax Amidate and the mass spec shows 984 Da, readers have standard Adamax. Both are legitimate research compounds. Neither is the compound on the label.

For the full breakdown of what every test on a COA actually measures and what documentation to require from any vendor, see the COA verification guide on RUO Codes. For vetted vendors carrying these compounds with documented mass spectrometry identification on every batch, see the approved vendor directory.

For research and educational purposes only. Not medical advice. Research peptides are not FDA-approved for human use.